Name：MIAO Qingfang

Department：Oncology

Tel: (8610)83150581

Email: miaoqf@imb.pumc.edu.cn

Education & Research Experience

2011/09 – Now Associate Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2004/08 – 2011/09 Assistant Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2001/08 – 2004/07 Ph.D. in microbial and biochemical pharmacy, Peking Union Medical College

1998/09 – 2001/07 M.S. in microbial and biochemical pharmacy, Jilin University

1994/08 – 1998/07 B.S. in biological pharmacy, Jilin University

Research Field：

Molecular-targeted cancer therapeutics, antibody-based drugs

Research Interests：

Dr. Miao has been engaged in molecular-targeted therapy and antibody-based drugs against cancer. She has built technology platforms about screening of monoclonal antibody as well as preparation and evaluation of antibody-drug conjugates (ADCs). She has been focusing on developing novel ADCs and fusion protein against different targets and further studying their antitumor effects and action mechanism to provide new candidates for tumor-targeted therapy.

Selected Publications

1. Wang R, Li L, Duan A, Li Y, Liu X, Miao Q*, Gong J*, Zhen Y. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.Cancer Lett. 2019 ; 448:84-93.

2. Wang R, Li L, Zhang S, Li Y, Wang X, Miao Q*, Zhen Y.A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas. Mol Oncol. 2018;12(3):339-355.  

3. Hu XY, Wang R, Jin J, Liu XJ, Cui AL, Sun LQ, Li YP, Li Y, Wang YC, Zhen YS, Miao QF*, Li ZR*. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. Mol Oncol. 2019;13(2):246-263.

4. Gong J, Guo F, Cheng W, Fan H, Miao Q*, Yang J*. Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models. Artif Cells Nanomed Biotechnol. 2020;48(1):408-414.

5. Gong JH, Zheng YB, Zhang MR, Wang YX, Yang SQ, Wang RH, Miao QF*, Liu XJ*, Zhen YS. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.Cancer Biol Ther. 2020;21(4):332-343.

Academic Appointments

Member of Monoclonal antibody Committee, China Medicinal Biotechnology Association